NEUP — Neuphoria Therapeutics Share Price
Last trade - 00:00- $8.37m
- $4.06m
- 18
- 29
- 52
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.61 | ||
| Price to Tang. Book | 40.92 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12.63 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -95.42% | ||
| Return on Equity | -48.99% | ||
| Operating Margin | -2308.69% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.03 | n/a | 0.19 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 1st, 2024
- Public Since
- December 21st, 1999
- No. of Shareholders
- 3,500
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 1,628,659
- Address
- 100 Summit Dr, BURLINGTON, 01803
- Web
- https://www.neuphoriatx.com/
- Phone
- Auditors
- WOLF & COMPANY, P.C.
Upcoming Events for NEUP
Similar to NEUP
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
As of Today at 22:14 UTC, shares in Neuphoria Therapeutics are trading at $5.14. This share price information is delayed by 15 minutes.
Shares in Neuphoria Therapeutics last closed at $5.14 and the price had moved by -55.35% over the past 365 days. In terms of relative price strength the Neuphoria Therapeutics share price has underperformed the S&P500 Index by -58.01% over the past year.
The overall consensus recommendation for Neuphoria Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNeuphoria Therapeutics does not currently pay a dividend.
Neuphoria Therapeutics does not currently pay a dividend.
Neuphoria Therapeutics does not currently pay a dividend.
To buy shares in Neuphoria Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $5.14, shares in Neuphoria Therapeutics had a market capitalisation of $8.37m.
Here are the trading details for Neuphoria Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: NEUP
Based on an overall assessment of its quality, value and momentum Neuphoria Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Neuphoria Therapeutics is $21.00. That is 308.62% above the last closing price of $5.14.
Analysts covering Neuphoria Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$11.02 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neuphoria Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +58.14%.
As of the last closing price of $5.14, shares in Neuphoria Therapeutics were trading -4.12% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Neuphoria Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Neuphoria Therapeutics' directors